Lisata Therapeutics, Inc. (LSTA)
NASDAQ: LSTA · Real-Time Price · USD
1.010
-0.010 (-0.98%)
At close: Nov 2, 2026, 4:00 PM EST
1.060
+0.050 (4.95%)
After-hours: Nov 2, 2026, 5:00 PM EST
Lisata Therapeutics Revenue
Lisata Therapeutics had revenue of $100.00K in the twelve months ending June 30, 2026, down -90.65% year-over-year. In the year 2025, Lisata Therapeutics had annual revenue of $170.00K, down -83.00%. That makes Lisata Therapeutics the 46,086th largest company in the world by revenue and 6,802nd in the United States.
Revenue (ttm)
$100.00K
Revenue Growth
-90.65%
P/S Ratio
94.52
Revenue / Employee
$4,762
Employees
21
Market Cap
9.10M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 170.00K | -830.00K | -83.00% |
| Dec 31, 2024 | 1.00M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 22.49M | 4.55M | 25.36% |
| Dec 31, 2014 | 17.94M | 3.27M | 22.30% |
| Dec 31, 2013 | 14.67M | 338.57K | 2.36% |
| Dec 31, 2012 | 14.33M | 4.28M | 42.58% |
| Dec 31, 2011 | 10.05M | -59.77M | -85.61% |
| Dec 31, 2010 | 69.82M | 58.26M | 503.72% |
| Dec 31, 2009 | 11.57M | 11.48M | 13,743.64% |
| Dec 31, 2008 | 83.54K | -148.12K | -63.94% |
| Dec 31, 2007 | 231.66K | 185.94K | 406.66% |
| Dec 31, 2006 | 45.72K | 10.46K | 29.67% |
| Dec 31, 2005 | 35.26K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
LSTA News
- 14 days ago - Lisata Therapeutics Proxy statement: Proxy filing - Filings
- 19 days ago - Lisata Therapeutics Appoints Jeff Farrow to Board of Directors - GlobeNewsWire
- 25 days ago - Lisata Therapeutics granted U.S. patent for certepetide in pancreatic cancer - TheFly
- 25 days ago - Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors - GlobeNewsWire
- 26 days ago - Lisata Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly - GlobeNewsWire
- 5 weeks ago - Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026 - GlobeNewsWire
- 6 weeks ago - Lisata Therapeutics Announces Acquisition of Marea Therapeutics and $225 Million Concurrent Private Placement - GlobeNewsWire